Learn about INVOKANA®, an SGLT2 inhibitor that helps lower blood sugar and risk of cardiovascular disease in adults. See full Prescribing & Safety Info. INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an INVOKANA mg once daily who have an eGFR of 60 mL/min/ m2. INVOKANA® is now the only oral diabetes treatment approved to in the INVOKANA® U.S. full Prescribing Information (PI).3 The PI also.

Author: Faedal Gardagami
Country: Belgium
Language: English (Spanish)
Genre: Business
Published (Last): 20 December 2013
Pages: 369
PDF File Size: 2.71 Mb
ePub File Size: 13.70 Mb
ISBN: 977-3-24813-207-9
Downloads: 13115
Price: Free* [*Free Regsitration Required]
Uploader: Shakalar

The PBAC recommended that cost-offsets be applied to canagliflozin to account for an increased rate of adverse events such as genital mycotic infections compared with sitagliptin. The risk of lower-limb amputations was observed at both the mg and mg once-daily dosage regimens. I Missed My Dose of Invokana. Invkoana theoretical risk for transmission of Creutzfeldt-Jakob disease CJD also is considered extremely remote.

However, Invokana is usually used as an “adjunct” added to to metformin, which boosts blood sugar control. Please see infokana Prescribing Information for more details. Worried you’ll need insulin?

Indication and Important Safety Information

Manage reactions according to signs and symptoms. Use of live vaccines could result in clinical infections, including disseminated infections. Rarely, treatment with TNF blockers may result in a lupus-like syndrome.

Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances:. If needed, Invokzna, the manufacturer of Invokana, may be able to offer cost assistance for Invokana if you qualify.


Factors that can increase the risk of developing epidural or ingokana hematomas in these patients include: The malignancies occurred after a median of 30 months after the first dose of therapy. Infusion reactions can also occur with subsequent infusions.

Control hypertension and correct hypokalemia before and during treatment. Tell your doctor if you take diuretics water pills to help invokanz fluid or digoxin used to treat heart problems. Some cases were fatal. Concurrent Active Severe Infections — Do not ijvokana to patients with severe infections until the infection resolves.

This site is intended for use in the United States. The FDA stated that patients who experience signs or symptoms of ketoacidosis such as trouble breathing, nausea, vomiting, abdominal [stomach] pain, confusion, unusual fatigue or sleepiness should contact their doctor immediately to determine if they have ketoacidosis, as your drug treatment may need to be stopped. The indirect comparison of mean change in HbA1c for canagliflozin mg and sitagliptin mg in combination with a sulfonylurea met the 0.

Prior to the introduction of post-infusion medication in invkkana trials, infusion reactions occurred up to 48 hours after infusion.

RxEconsult | Home

Monitor patients frequently for signs and symptoms of neurological impairment. Perform appropriate tests, if indicated, to confirm AI. Invokana works in the kidneys, so you should not use Invokana lnvokana you have severe kidney problems or are on kidney dialysis.


In patients who take UGT enzyme inducers such as rifampin, phenytoin, phenobarbital, or ritonavirhigher doses of Invokana may be needed to control blood sugar. The onset of rash occurred at a median of 82 days. Stop the infusion if the patient develops signs of anaphylaxis. Clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses.

Signs of low blood sugar include: Increased bleeding in hemophiliacs has been reported in invo,ana receiving protease inhibitors. Increases in Invokkana levels associated with canagliflozin were also noted.

Your doctor will review how well your kidney works before and during treatment with Invokana; you need good kidney function to take Invokana as that’s where the drug works. The PBAC noted no statistically significant differences in the head to head trials and indirect comparisons between canagliflozin and sitagliptin in terms of patients with at least one adverse event, with at least one serious adverse event and with adverse events leading to discontinuation.

Before you take Invokana or other medications containing canagliflozin, tell your doctor if you have a history of amputation, nerve damage, or peripheral vascular disease.